Published in Neurologist on January 01, 2010
Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol (2011) 1.62
Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc (2011) 0.99
Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism Relat Disord (2014) 0.96
Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias. Am J Alzheimers Dis Other Demen (2010) 0.95
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. Transl Neurodegener (2013) 0.87
Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies. J Mol Neurosci (2011) 0.82
Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegener Dis Manag (2011) 0.80
New perspective on parkinsonism in frontotemporal lobar degeneration. J Mov Disord (2013) 0.79
Managing differences: care of the person with frontotemporal degeneration. J Gerontol Nurs (2013) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
The FAB: a Frontal Assessment Battery at bedside. Neurology (2000) 8.93
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry (1994) 5.40
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol (2008) 3.99
The logopenic/phonological variant of primary progressive aphasia. Neurology (2008) 3.95
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain (2006) 2.52
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
Survival in frontotemporal dementia. Neurology (2003) 2.48
Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage (2008) 2.36
Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology (1990) 2.36
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Primary progressive aphasia. Longitudinal course, neuropsychological profile, and language features. Arch Neurol (1990) 2.03
TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol (2008) 2.02
A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol (2007) 1.95
Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol (1997) 1.94
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain (2008) 1.84
Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology (2006) 1.80
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 1.64
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol (2007) 1.60
New directions for frontotemporal dementia drug discovery. Alzheimers Dement (2007) 1.53
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain (2006) 1.51
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol (2007) 1.45
Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry (2007) 1.43
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis (2008) 1.43
Corticobasal syndrome associated with the A9D Progranulin mutation. J Neuropathol Exp Neurol (2007) 1.39
Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging (2006) 1.39
Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab (2001) 1.38
Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord (2008) 1.34
Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat (2008) 1.30
Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol (2007) 1.29
Screening for frontotemporal dementias and Alzheimer's disease with the Philadelphia Brief Assessment of Cognition: a preliminary analysis. Dement Geriatr Cogn Disord (2007) 1.26
Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology (2000) 1.20
Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet (2007) 1.16
Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord (2007) 1.15
Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord (2004) 1.15
Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol (2003) 1.14
Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging (2004) 1.11
Relationship between frontotemporal dementia and corticobasal degeneration/progressive supranuclear palsy. Dement Geriatr Cogn Disord (2004) 1.11
Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry (1997) 1.11
Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement (2007) 1.10
Hippocampal sclerosis and ubiquitin-positive inclusions in dementia lacking distinctive histopathology. Dement Geriatr Cogn Disord (2004) 1.10
Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord (2006) 1.09
Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr (2008) 1.08
Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) (2003) 1.06
Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. J Clin Psychiatry (2008) 1.05
A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry (2008) 1.02
The psychosocial impact of young onset dementia on spouses. Am J Alzheimers Dis Other Demen (2007) 1.00
Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology (2002) 0.98
Treatment for anomia in semantic dementia. Semin Speech Lang (2008) 0.97
Repeat and Point: differentiating semantic dementia from progressive non-fluent aphasia. Cortex (2007) 0.93
Rate of cognitive change measured by neuropsychologic test performance in 3 distinct dementia syndromes. Alzheimer Dis Assoc Disord (2007) 0.91
Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. J Neurol (2008) 0.91
Driving abilities in frontotemporal dementia patients. Dement Geriatr Cogn Disord (2006) 0.90
Utility of behavioral versus cognitive measures in differentiating between subtypes of frontotemporal lobar degeneration and Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 0.86
Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord (2008) 0.85
Support to family carers of patients with frontotemporal dementia. Aging Ment Health (2008) 0.82
Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry (2003) 0.79
Focal degenerative dementia syndromes. Clin Geriatr Med (2001) 0.76
Recent advances in the understanding of tau protein and movement disorders. Curr Opin Neurol (2001) 0.76